102 related articles for article (PubMed ID: 793499)
1. Failure of customary treatment in chronic active liver disease: causes and management.
Schalm SW; Ammon HV; Summerskill WH
Ann Clin Res; 1976 Jun; 8(3):221-7. PubMed ID: 793499
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission.
Czaja AJ; Ammon HV; Summerskill WH
Gastroenterology; 1980 Mar; 78(3):518-23. PubMed ID: 7351290
[TBL] [Abstract][Full Text] [Related]
3. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome.
Geubel AP; Baggenstoss AH; Summerskill WH
Gastroenterology; 1976 Sep; 71(3):444-9. PubMed ID: 950095
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy in chronic liver disease.
Sherlock S
Minerva Med; 1978 Aug; 69(38):2605-9. PubMed ID: 714260
[TBL] [Abstract][Full Text] [Related]
6. [Immunosuppressive treatment of chronic liver diseases in the clinical biochemical, immunological and histological evaluation of the liver].
Boroń P; Szpakowicz T; Bobrowska E; Boroń-Kaczmarska A; Prokopowicz D; Borzuchowska A
Z Gesamte Inn Med; 1981 May; 36(10):318-21. PubMed ID: 7303757
[TBL] [Abstract][Full Text] [Related]
7. Drug therapy reviews: chronic hepatitis.
Augur NA
Am J Hosp Pharm; 1978 Oct; 35(10):1222-6. PubMed ID: 358829
[TBL] [Abstract][Full Text] [Related]
8. [Immunosuppressive treatment of patients with chronic active HBsAg positive hepatitis].
Tanno H; Fay O; Roldán L; Vorovioff J
Acta Gastroenterol Latinoam; 1982; 12(4):323-32. PubMed ID: 7185230
[TBL] [Abstract][Full Text] [Related]
9. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis.
Davis GL; Czaja AJ; Ludwig J
Gastroenterology; 1984 Dec; 87(6):1222-7. PubMed ID: 6489694
[TBL] [Abstract][Full Text] [Related]
10. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.
Summerskill WH; Korman MG; Ammon HV; Baggenstoss AH
Gut; 1975 Nov; 16(11):876-83. PubMed ID: 1104411
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic active hepatitis. An analysis of three controlled trials.
Wright EC; Seeff LB; Berk PD; Jones A; Plotz PH
Gastroenterology; 1977 Dec; 73(6):1422-30. PubMed ID: 334625
[No Abstract] [Full Text] [Related]
12. Response to steroid and immunosuppressor therapy in patients with chronic active liver disease (CALD) non-related to the presence of hepatitis Bs antigen.
Robles G; Centeno F; Uribe M; Guevara L
Rev Invest Clin; 1980; 32(3):271-6. PubMed ID: 7444226
[No Abstract] [Full Text] [Related]
13. [Indications, method and effectiveness of immunosuppressive treatment in chronic active hepatopathies. 3. Evolution of the immunologic picture. IV. Improvement of the functional parameters].
Nicolescu T; Bittman E; Stoiculescu P; Bordeianu A; Boroş I; Jinga V; Moucha R; Ciontescu L
Med Interna (Bucur); 1974 Apr; 26(4):465-78. PubMed ID: 4839353
[No Abstract] [Full Text] [Related]
14. Treatment of chronic active hepatitis (CAH): a retrospective review of 130 patients.
Giusti G; Ruggiero G; Galanti B; Piccinino F; Russo M; Galante D; Sagnelli E; Utili R; Pasquale G; Nardiello S; Aloisio V
Hepatogastroenterology; 1981 Oct; 28(5):245-9. PubMed ID: 7047337
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-year follow-up].
Lhermitte F; Marteau R; de Saxcé H
Rev Neurol (Paris); 1987; 143(2):98-107. PubMed ID: 3299618
[TBL] [Abstract][Full Text] [Related]
16. Life-saving immunosuppressive treatment in severe autoimmune chronic active hepatitis.
Maggiore G; Bernard O; Hadchouel M; Alagille D
J Pediatr Gastroenterol Nutr; 1985 Aug; 4(4):655-8. PubMed ID: 4032180
[TBL] [Abstract][Full Text] [Related]
17. [Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome: therapeutic features in 5 patients].
Cheikh I; Said Y; Chaabouni H; Ouerghi H; Ben Ammar A
Ann Med Interne (Paris); 2003 Feb; 154(1):7-11. PubMed ID: 12746654
[TBL] [Abstract][Full Text] [Related]
18. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.
Schalm SW; Summerskill WH; Go VL
Gastroenterology; 1977 May; 72(5 Pt 1):910-3. PubMed ID: 849821
[TBL] [Abstract][Full Text] [Related]
19. Current therapy for autoimmune hepatitis.
Montano Loza AJ; Czaja AJ
Nat Clin Pract Gastroenterol Hepatol; 2007 Apr; 4(4):202-14. PubMed ID: 17404588
[TBL] [Abstract][Full Text] [Related]
20. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation.
Pedrosa MC; Rohrer RM; Kaplan MM
Clin Transplant; 1995 Aug; 9(4):322-5. PubMed ID: 7579741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
